Stockholm, Sweden, October 18, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Eisai will present additional data on the anti-amyloid (Aβ) protofibril antibody BAN2401 clinical Phase 2b study at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) conference, October 24-27, 2018 in Barcelona, Spain.
The presentation will be given during the symposium “Clinical and Biomarker Updates from BAN2401 Study 201 in Early AD” where additional data will be highlighted from the BAN2401 Phase 2b study (ClinicalTrials.gov identifier: NCT01767311).
Presentation of BAN2401 at CTAD 2018:
|Product, Session Number||Title and scheduled presentation date and time|
Session no.: Symposium 3
|Clinical and Biomarker Updates from BAN2401 Study 201 in
October 25 (Thursday), 14:30 – 15:30 CEST
(02:30 – 03:30 p.m. CEST)
The BAN2401 Phase 2b study presentation at CTAD will be webcast live on Thursday, October 25 at 14:30 – 15:30 CEST. To access the live webcast, please visit https://www.eisai.com/ir/index.html.
BioArctic previously announced results from BAN2401 Phase 2b study presented by Eisai during the Alzheimer’s Association International Conference (AAIC) in July 2018. More information in the press releases: “BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer’s disease” and “BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer’s disease presented at AAIC 2018”.
BioArctic is striving to develop disease-modifying treatments in order to contribute to addressing unmet medical needs of Alzheimer patients and their families. Today there is no disease-modifying treatment on the market for these patients.
This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agent will successfully complete clinical development or gain health authority approval.
For more information, please contact
Gunilla Osswald, PhD, CEO, BioArctic AB
Telephone: + 46 8 695 69 30
Christina Astrén, Director IR & Communications, BioArctic AB
Telephone: + 46 70 835 43 36
Notes to editors
Please note CTAD embargo policy: All materials submitted to CTAD are embargoed for publication and broadcast until after the officially scheduled date and time of presentation, symposia or poster session.
BAN2401 is a humanized monoclonal antibody that is the result of a strategic research alliance between BioArctic and Eisai. BAN2401 selectively binds to neutralize and eliminate soluble, toxic amyloid-beta aggregates that are thought to contribute to the neurodegenerative process in Alzheimer’s disease. As such, BAN2401 has the potential to have an effect on the disease pathology and to slow down the progression of the disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer’s disease pursuant to an agreement concluded with BioArctic in December 2007. Eisai is responsible for the Phase 2b study and the development of BAN2401 for Alzheimer’s disease. In March 2014, Eisai and Biogen entered into a joint development and commercialization agreement for BAN2401.
About the collaboration between BioArctic and Eisai
Since 2005, BioArctic has long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer’s disease. The most important agreements are the development and commercialization agreement on the BAN2401 antibody, which was signed in December 2007, and the development and commercialization agreement on the antibody BAN2401 back-up for Alzheimer’s disease, which was signed in May 2015. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer’s disease.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (STO:BIOA B). www.bioarctic.com.
About Eisai Co., Ltd.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. Eisai defines their corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which Eisai calls their human health care (hhc) philosophy. With approximately 10,000 employees working across the global network of R&D facilities, manufacturing sites and marketing subsidiaries, Eisai strives to realize their hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.
Leveraging the experience gained from the development and marketing of Aricept®, a treatment for Alzheimer’s disease and dementia with Lewy bodies, Eisai has been working to establish a social environment that involves patients in each community in cooperation with various stakeholders including the government, healthcare professionals and care workers, and is estimated to have held over ten thousand dementia awareness events worldwide. As a pioneer in the field of dementia treatment, Eisai is striving to not only develop next generation treatments but also to develop diagnosis methods and provide solutions. For more information about Eisai Co., Ltd., please visit www.eisai.com.
This information was submitted for publication at 01:30 a.m. CET on October 18, 2018.